-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Vera Therapeutics, Lowers Price Target to $66

Benzinga·11/06/2026 16:11:28
Listen to the news
Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $76 to $66.